About Polatuzumab vedotin
Class: | Antineoplastic agent; CD79b-directed antibody-drug conjugate; Monoclonal antibody.
Use: | Polatuzumab vedotin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab after at least two prior therapies.
Adult dose: | The recommended dose is 1.8 mg/kg administered as an intravenous infusion every 21 days for 6 cycles in combination with bendamustine and rituximab.
Pediatric dose: | Sa
Drug Class
Antineoplastic agent; CD79b-directed antibody-drug conjugate; Monoclonal antibody.
Uses & Indications
Polatuzumab vedotin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab after at least two prior therapies.
Storage Requirements
Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
Manufacturer & Packaging
Manufacturer: F.Hoffmann - La Roche Ltd[Basel;Switzerland], Switzerland
Package Size
1 Glass Vial
Price & Supplier
Price in UAE: AED 10845.00
Dosage Information
Adult Dose
The recommended dose is 1.8 mg/kg administered as an intravenous infusion every 21 days for 6 cycles in combination with bendamustine and rituximab.
Pediatric Dose
Safety and efficacy in pediatric patients have not been established; therefore, no dosing information is available.
Side Effects
Common side effects include peripheral neuropathy, fatigue, diarrhea, fever, nausea, anemia, thrombocytopenia, and decreased appetite.
Contraindications & Precautions
Contraindicated in patients with a known hypersensitivity to polatuzumab vedotin or any of its components.
Important Warnings
Serious and potentially fatal side effects include peripheral neuropathy, infusion-related reactions, myelosuppression, serious infections, hepatotoxicity, and tumor lysis syndrome. Monitor patients closely for these conditions.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.